Propanc Biopharma receives US patent for enzyme composition in cancer treatment.

Propanc Biopharma has received a certificate of grant from the US Patent & Trademark Office for its "proenzyme composition" patent, specifically covering a future clinical dose of its lead asset, PRP. This is the fourth US patent granted by the company, and adds to its intellectual property portfolio of 90 patents filed in major jurisdictions. The patent is an important part of the IP portfolio as the company advances to a Phase 1B, First-In-Human study in advanced cancer patients.